Vanhanen H - Search Results

1

Serum cholesterol response to dietary cholesterol and apoprotein E phenotype.

Miettinen TA, Gylling H, Vanhanen H. Miettinen TA, et al. Among authors: vanhanen h. Lancet. 1988 Nov 26;2(8622):1261. doi: 10.1016/s0140-6736(88)90862-8. Lancet. 1988. PMID: 2903999 No abstract available.

2

Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects.

Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Vanhanen HT, et al. Clin Sci (Lond). 1994 Jul;87(1):61-7. doi: 10.1042/cs0870061. Clin Sci (Lond). 1994. PMID: 8062521 Clinical Trial.

3

Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population.

Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Miettinen TA, et al. Among authors: vanhanen h. N Engl J Med. 1995 Nov 16;333(20):1308-12. doi: 10.1056/NEJM199511163332002. N Engl J Med. 1995. PMID: 7566021 Clinical Trial.

4

Apolipoprotein E phenotype and cholesterol metabolism in familial hypercholesterolemia.

Gylling H, Kuusi T, Vanhanen H, Miettinen TA. Gylling H, et al. Among authors: vanhanen h. Atherosclerosis. 1989 Nov;80(1):27-32. doi: 10.1016/0021-9150(89)90064-6. Atherosclerosis. 1989. PMID: 2604754

5

Cholesterol absorption, elimination, and synthesis related to LDL kinetics during varying fat intake in men with different apoprotein E phenotypes.

Miettinen TA, Gylling H, Vanhanen H, Ollus A. Miettinen TA, et al. Among authors: vanhanen h. Arterioscler Thromb. 1992 Sep;12(9):1044-52. doi: 10.1161/01.atv.12.9.1044. Arterioscler Thromb. 1992. PMID: 1525119

6

Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment.

Vanhanen HT, Blomqvist S, Ehnholm C, Hyvönen M, Jauhiainen M, Torstila I, Miettinen TA. Vanhanen HT, et al. J Lipid Res. 1993 Sep;34(9):1535-44. J Lipid Res. 1993. PMID: 8228636 Clinical Trial.

7

Dietary sitostanol related to absorption, synthesis and serum level of cholesterol in different apolipoprotein E phenotypes.

Miettinen TA, Vanhanen H. Miettinen TA, et al. Among authors: vanhanen h. Atherosclerosis. 1994 Feb;105(2):217-26. doi: 10.1016/0021-9150(94)90052-3. Atherosclerosis. 1994. PMID: 8003098 Clinical Trial.

8

Effect of statins on C-reactive protein in patients with coronary artery disease.

Strandberg TE, Vanhanen H, Tikkanen MJ. Strandberg TE, et al. Among authors: vanhanen h. Lancet. 1999 Jan 9;353(9147):118-9. doi: 10.1016/S0140-6736(05)76154-7. Lancet. 1999. PMID: 10023901 Clinical Trial. No abstract available.

9

Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination.

Gylling H, Vanhanen H, Miettinen TA. Gylling H, et al. Among authors: vanhanen h. Eur J Clin Pharmacol. 1989;37(2):111-5. doi: 10.1007/BF00558216. Eur J Clin Pharmacol. 1989. PMID: 2792164 Clinical Trial.

10

Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study).

Olkinuora JT, Viikari J, Vanhanen H, Makkonen N, Kalliomäki T. Olkinuora JT, et al. Among authors: vanhanen h. Scand Cardiovasc J. 2006 Jun;40(3):160-6. doi: 10.1080/14017430600801675. Scand Cardiovasc J. 2006. PMID: 16798663 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results